Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Abstract Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH). Methods Thirty-ei...

Full description

Bibliographic Details
Main Authors: Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Arthritis Research & Therapy
Subjects:
Mildly elevated mPAP
Borderline pulmonary hypertension
Exercise PH
Ambrisentan
Treatment
Placebo-controlled
Online Access:http://link.springer.com/article/10.1186/s13075-019-1981-0

Internet

http://link.springer.com/article/10.1186/s13075-019-1981-0

Similar Items